ArticleFrontiers in immunology2022

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.

Shayista Akbar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.